Amylyx Pharmaceuticals, Inc.
AMLX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001658551
In the last 90 days, Amylyx Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 206 institutions reported holding it in 13F filings for Q2 2026, worth $2.07B in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Amylyx Pharmaceuticals, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 95 | 1 | 133 | +39 |
| Shares | 37.3M | 2.79K | 48.6M | +11.3M (+30.3%) |
| Value | $1.05B | $78.6K | $1.79B | +$748.1M (+71.6%) |
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (47)
Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
Sold out (8)
Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,023,214 | $28.8M |
| Marshall Wace, LLP | 341,064 | $9.60M |
| Pura Vida Investments, LLC | 68,652 | $1.93M |
| Caption Management, LLC | 42,947 | $1.21M |
| Susquehanna International Group, LLP | 10,285 | $290.0K |
| Loring Wolcott & Coolidge Fiduciary Advisors LLP | 1,803 | $51.0K |
| Cowen and Company, LLC | 20,800 | $7.00K |
| Ronald Blue Trust, Inc. | 15 | $0 |
Not filed for Q4 2022 yet (1)
Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Jefferies Group LLC | 2,791 | $78.6K |